T cell therapy for KRAS-mutated advanced solid tumors
Part of Cancer clinical trials.
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have an advanced solid tumor that cannot be removed by surgery and no longer responds to standard treatments, or you cannot tolerate standard treatments
- You have a specific genetic marker called HLA-A*11:01
- Your tumor has either a KRAS G12V or KRAS G12D mutation
- You are in fairly good health (ECOG score 0 or 1) and have adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
This trial tests a new treatment using your own immune cells (T cells) that are modified to find and attack cancer cells with a specific genetic change (KRAS G12V or G12D). It is for people with advanced cancer that has not responded to standard treatments.
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
This trial tests an experimental cell therapy that uses your own immune cells to attack cancers with a specific gene change (KRAS G12V). It may be an option if other treatments haven't worked.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
Hear when a new Tumor, Solid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.